Otonomy, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$11.6M
Doctors Paid
395
Transactions
1,758
2021 Total
$123,263
Payment Breakdown by Category
Research$10.7M (92.9%)
Consulting$477,801 (4.1%)
Food & Beverage$13,314 (0.1%)
Royalty/License$12,987 (0.1%)
Travel$10,882 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $10.7M | 1,008 | 92.9% |
| Consulting Fee | $477,801 | 117 | 4.1% |
| Grant | $200,671 | 3 | 1.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $105,527 | 61 | 0.9% |
| Food and Beverage | $13,314 | 420 | 0.1% |
| Royalty or License | $12,987 | 17 | 0.1% |
| Travel and Lodging | $10,882 | 25 | 0.1% |
| Education | $1,919 | 106 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $1,500 | 1 | 0.0% |
Payments by Type
Research
$10.7M
1,008 transactions
General
$824,601
750 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Prospective, Randomized, Double Blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease | $6.0M | 11 | 178 |
| A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-313 Given as a Single Intratympanic Injection in Subjects With Subjective Tinnitus | $2.3M | 1 | 110 |
| STUDY OF OTO-104 IN SUBJECTS WITH UNILATERAL MENIERE'S DISEASE | $842,639 | 2 | 283 |
| A 6-MONTH EXTENSION STUDY OF OTO-104 IN MENIERE'S DISEASE | $538,440 | 1 | 238 |
| A randomized, Double-Blind, Placebo-Controlled Phase 1/2 study of OTO-413 given as a single intratymoanic injection in subjects with speech-in-noise hearing impairment | $351,801 | 0 | 23 |
| STUDY OF OTO-104 IN SUBJECTS AT RISK FROM CISPLATIN-INDUCED HEARING LOSS | $318,156 | 10 | 62 |
| PHASE 3 STUDY OF OTO-201 IN ACUTE OTITIS EXTERNA | $175,057 | 4 | 70 |
| A randomized, Double-Blind, Placebo-Controlled Phase 1/2 study of OTO-413 given as a single Intratympanic injection in subjects with speech-in-noise hearing impairment | $119,163 | 0 | 11 |
| OPEN-LABEL STUDY OF OTO-201 IN PEDIATRIC SUBJECTS WITH A HISTORY OF OTITIS MEDIA REQUIRING TYMPANOSTOMY TUBES | $71,042 | 1 | 22 |
| A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-413 Given as a Single Intratympanic Injection in Subjects With Speech-in-noise Hearing Impairment | $15,492 | 0 | 1 |
| A 6-Month, Multicenter, Phase 3, Open-Label Extension Safety Study of OTO-104 Given At 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease | $10,500 | 0 | 4 |
| A prospective, randomized, double blind, placebo-controlled, multicenter, Phase 3 efficacy and safetystudy of OTO-104 given as a single intratympanic injection in subjects with unilateral Meniere's disease. | $5,450 | 0 | 2 |
| A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease | $4,004 | 0 | 1 |
| An 8-Week, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Administration in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes | $1,138 | 0 | 1 |
| A 6-MONTH EXTENSION STUDY OF OTO-104 IN MENIERES DISEASE | $80.00 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 10
| Doctor | Specialty | Location | Total | 2017 |
|---|---|---|---|---|
| Dorise Yang, Md, MD | Otolaryngology/Facial Plastic Surgery | Farmington Hills, MI | $18.88 | $0 |
| Dr. Brett Scotch, D.o, D.O | Otolaryngology | Wesley Chapel, FL | $18.83 | $0 |
| Christine Gilliam, Md, MD | Otolaryngology | San Antonio, TX | $18.56 | $0 |
| Richard Smith, M.d, M.D | Otolaryngology | Danville, VA | $18.43 | $0 |
| Samuel Meadema, Md, MD | Otolaryngology | Danville, VA | $18.43 | $0 |
| James Masdon, M.d, M.D | Otolaryngology | Guntersville, AL | $18.33 | $0 |
| Dr. Ronald Dong, M.d, M.D | Otolaryngology | Stockton, CA | $18.23 | $0 |
| Dr. Spencer Lowe, Md, MD | Otolaryngology | Stockton, CA | $18.23 | $0 |
| Brian Stater, M.d, M.D | Otolaryngology | Portland, OR | $18.19 | $0 |
| Stefan Zechowy, M.d, M.D | Otolaryngology | Santa Rosa, CA | $18.19 | $0 |
| Mark Homicz, M.d, M.D | Otolaryngology | Santa Rosa, CA | $18.19 | $0 |
| Stephanie Huang, M.d, M.D | Facial Plastic Surgery | Santa Rosa, CA | $18.19 | $0 |
| David Quenelle, M.d, M.D | Otolaryngology | Santa Rosa, CA | $18.19 | $0 |
| Dr. William Hawkins, Md, MD | Otolaryngology | Tulsa, OK | $18.12 | $0 |
| Dr. Tom Hamilton, Do, DO | Otolaryngology | Tulsa, OK | $18.12 | $0 |
| Unknown Provider | — | — | $18.10 | $0 |
| Dr. Richard Busch, Md, MD | Otolaryngology | Bakersfield, CA | $17.97 | $0 |
| Dr. William Zimmerman, Md, MD | Specialist | Framingham, MA | $17.89 | $0 |
| Dr. Orville Dyce, M.d, M.D | Otolaryngology | Hartsville, SC | $17.83 | $0 |
| Wallace Duff, M.d, M.D | Otolaryngology | Omaha, NE | $17.77 | $0 |
| Jamie Frantz, M.d, M.D | Orthopaedic Surgery | Roscoe, IL | $17.70 | $0 |
| Unknown Provider | — | — | $17.68 | $0 |
| David Malis, Md, MD | Pediatric Otolaryngology | Melbourne, FL | $17.53 | $0 |
| Judy Liu, Md, MD | Otolaryngology | Irvine, CA | $17.30 | $0 |
| Dr. Mark Frey, M.d, M.D | Otolaryngology | Canton, NY | $17.28 | $0 |
About Otonomy, Inc.
Otonomy, Inc. has made $11.6M in payments to 395 healthcare providers, recorded across 1,758 transactions in the CMS Open Payments database. In 2021, the company paid $123,263. The top product by payment volume is OTO-313 ($513,049).
Payments were distributed across 27 medical specialties. The top specialty by payment amount is Internal Medicine ($339,126 to 5 doctors).
Payment categories include: Food & Beverage ($13,314), Consulting ($477,801), Research ($10.7M), Travel & Lodging ($10,882), Royalties ($12,987).
Otonomy, Inc. is associated with 4 products in the CMS Open Payments database, including OTO-313, OTO-413, and OTO-104.